Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 08:35 am Sale | 13G | Replimune Group Inc. REPL | Omega Fund IV L.P. | 2,709,991 4.000% | -540,000 (-16.62%) | View |
| 2024-02-14 4:44 pm Sale | 13G | Replimune Group Inc. REPL | Omega Fund IV L.P. | 3,249,991 5.500% | -360,487 (-9.98%) | View |
| 2023-02-13 4:49 pm Sale | 13G | Replimune Group Inc. REPL | Omega Fund IV L.P. | 3,610,478 7.200% | -1,445,074 (-28.58%) | View |
| 2022-02-14 3:18 pm Sale | 13G | Replimune Group Inc. REPL | Omega Fund IV L.P. | 5,055,552 10.600% | -274,231 (-5.15%) | View |
| 2021-02-12 2:32 pm Sale | 13G | ESSA Pharma Inc. EPIX | Omega Fund IV L.P. | 777,996 2.300% | -1,004,155 (-56.35%) | View |
| 2020-08-06 4:47 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Omega Fund IV L.P. | 1,670,370 6.900% | 1,670,370 (New Position) | View |
| 2020-02-14 1:14 pm Purchase | 13G | Replimune Group Inc. REPL | Omega Fund IV L.P. | 5,329,783 16.500% | 226,328 (+4.43%) | View |
| 2020-02-14 12:01 pm Sale | 13G | ESSA Pharma Inc. EPIX | Omega Fund IV L.P. | 1,782,151 8.600% | -20,520,878 (-92.01%) | View |
| 2020-02-14 11:02 am Unchanged | 13G | Translate Bio Inc. TBIO | Omega Fund IV L.P. | 2,437,603 4.000% | 0 (Unchanged) | View |